Why the UK Should Consider Gene Expression Testing in Prostate Cancer

Area of Science:

• Oncology
• Genomics
• Biomarkers

Background:

• Prostate cancer treatment personalization is increasing in the USA using gene expression biomarkers.
• These advanced prognostic tools are currently unavailable in the UK.
• Traditional methods like Gleason grade are subjective and have suboptimal performance in risk stratification.

Purpose of the Study:

• To highlight the need for objective biological genotypes over subjective histological phenotypes.
• To review the limitations of current clinical and pathological variables for patient risk stratification.
• To advocate for the adoption of genomic classifiers in the UK for improved prostate cancer management.

Main Methods:

• Review of existing literature on prognostic gene expression biomarkers.
• Analysis of the performance of genomic classifiers versus traditional risk stratification methods.
• Discussion of the implications for UK clinical guidelines and healthcare policy.

Main Results:

• Genomic classifiers demonstrate superior accuracy in distinguishing indolent from aggressive prostate cancer.
• These classifiers provide objective biological insights independently of Gleason grade or stage.
• Clinical and pathological variables show limitations in precise patient risk stratification.

Conclusions:

• There is a critical need for improved prognostic biomarkers in prostate cancer care.
• The UK should transition beyond the D'Amico risk classification schema.
• Genomic classifiers represent a significant advancement for personalized prostate cancer treatment in the UK.